Pliva D.d.

Glaxo Group Limited

Pliva, Farmaceutska, Kemijska, Prehrambena I Kozmeticka Industrija,

Pliva Hrvatska D.o.o.

Pliva, Farmaceutska Industrija, Dionicko Drustvo

Miljenko Dumic

Darko Filic

Gorjana Lazarevski

Aleksandar Danilovski

Mladen Vinkovic

Daniele Andreotti

Sergio Lociuro

Antun Hutinec

Stefano Biondi

Jessica Tibasco

Drazen Pavlovic

Stjepan Mutak

Nedjeljko Kujundzic

Zorica Marusic-Istuk

Federica Damiani

Marijan Tudja

Mirjana Bukvic Krajacic

Marko Djerek

Andrea Berdik

Suleman Alihodzic

Blanka Jamnicky

Alfredo Paio

Vlado Stimac

Katica Lazaric

Dominik Cincic

Alojz Dumbovic

Ernest Mestrovic

Marina Oresic

Ilaria Bientinesi

Dejan Kresimir Bucar

Zdravka Knezevic

Manuela Ciraco

Vesna Erakovic

Anna Quaglia

Wolfgang Schoenfeld

Andrea Hasenohrl

Substantially pure isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A having the Formula I: wherein S is an organic solvent which is at least partially miscible with water, x is 1, 1.25, 1.5 or 2, y is 0, 0.5, or 1, the pseudopolymorph being characterized by the monoclinic space group P2and average unit cell parameters comprising: crystal axis lengths of a=15.5-17.0 &#x212b;, b=15.5-17.0 &#x212b;, and c=17.5-19.5 &#x212b;, and angles between the crystal axes of &#x3b1;=&#x3b3;=90&#xb0; and &#x3b2;=106&#xb0;-112&#xb0;. In addition, this disclosure is directed to processes for the preparation of the substantially pure isostructural pseudopolymorphs of Formula I; to pharmaceutical compositions containing substantially pure isostructural pseudopolymorphs of Formula I; and to a method for the treatment of bacterial and protozoan infections, and inflammation-related diseases by administration of a pharmaceutical composition containing the substantially pure isostructural pseudopolymorphs of Formula I.

Isostructural pseudopolymorphs of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A

The present invention relates to 14 or 15 membered macrolides substituted at the 4' position of formula (I) and pharmaceutically acceptable salts and solvates thereof, to processes for their preparation and their use in therapy or prophylaxis of systemic or topical bacterial infections in a human or animal body 

Macrolides

The invention relates to compositions of N-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsul fonamide and cyclic oligosaccharides with increased release, to methods for their preparation, to pharmaceutical froms containing them as well as to their use.

Compositions of N-(methylethylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides

9a-N-[N'-(phenylsulfonyl)carbamoyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and of 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A and their pharmaceutically acceptable addition salts with inorganic or organic acids are provided, along with a process for their preparation, pharmaceutical compositons, and use in treating bacterial infections.

9a-N-[N'-(phenylsulfonyl)carbamoyl] derivatives of 9-deoxo-9-dihydro-9a-aza-9a-homoerythromycin A and of 5-O-desosaminyl-9-deoxo-9-dihydro-9a-aza-9a-homoerythronolide A

Novel O-substituted or O-unsubstituted 6-sulfonamido-1,3-dioxepane-5-ols having hypoglycemic activity are obtained from 6-amino-1,3-dioxepane-5-ol, tetrahydro-6H-[1,3]-dioxepino[5,6-d]oxazole, 5,6-epoxy-1,3-dioxepane or N-sulfonyl-tetrahydro-1H,4H-[1,3]-dioxepino[5,6-b]azirine as starting materials.

Sulfonamidodioxepanes, methods of preparation, intermediates, salts and

Growing community of inventors

Zagreb, Croatia

Miljenko Dumic